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newBorn screening summary: Present anD Future
Newborn babies are screened for a selected panel of serious, early onset genetic 
disorders. Metabolic newborn screening is the screening of a specific population 
(neonates) using indirect measures of genetic disorders, rather than direct genetic 
(DNA) testing. 
Metabolic screening looks for evidence of an existing disorder, whereas DNA testing 
is a risk assessment (i.e. predictive, not diagnostic) for a disorder.
The indirect measures used in newborn screening are of chemical compounds 
(metabolites) found in the bloodstream, which are part of metabolism (the process 
of using food). 
These metabolites are analysed in a blood sample taken two to three days after birth. 
This allows enough time for the baby’s own metabolism to take effect, without the 
influence of the maternal metabolism left over from pregnancy. Abnormal levels 
(those outside a defined range) are considered suggestive of a disorder. Such results 
are followed up with retesting and/or further investigation.
Not all positive results are true positives: some are termed false positives upon further 
investigation. A small number of negative results may turn out to be false too.
Pre-2007, the metabolites were analysed using a combination of biochemical and 
antibody-based detection techniques. Seven rare disorders were tested for in New 
Zealand until recently: phenylketonuria (PKU), maple syrup urine disease (MSUD), 
galactosaemia (GALT), biotinidase deficiency (BIOT), congenital hypothyroidism 
(CH), congenital adrenal hyperplasia (CAH), and cystic fibrosis (CF). It was 
estimated that this newborn screening detected thirty to thirty-five affected babies 
per annum.1
The New Zealand screening panel has recently been expanded by the introduction 
of a mass spectrometry system (tandem mass spectrometry). This technology can 
simultaneously measure many metabolites. The number of disorders in the screening 
panel will increase by twenty-one (in addition to the seven disorders on the old panel).
Direct genetic (DNA) testing is sometimes used as a follow-up to a positive result. 
There are currently, however, no genetic tests that are more efficient and cost effective 
than indirect metabolic screening. DNA screening technology is likely to become 
cheaper and more effective in the future.
A disorder may be caused by one change (or more) out of many different changes 
to DNA sequence or structure. Some changes have more severe consequences than 
other changes, and severity can vary from person to person, even for those with the 
same causative mutations.
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Difficulties with direct screening of DNA include assessment of the risk of developing 
a disorder based on a positive result, and gaps in knowledge regarding the different 
causes of a particular disorder.
Direct genetic screening of newborns is a possibility for the future. In the near to 
medium term future, DNA screening (as opposed to diagnostic or follow-up testing) 
may be used as an adjunct to newborn metabolic screening, but is unlikely to replace 
it altogether. Long-term, it is likely that unanticipated technologies will exist and may 
be used for the purpose.
Figure 1: The Guthrie card is used to collect blood samples for testing by the newborn 
metabolic screening programme in New Zealand
Source: Screening Matters newsletter2
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1  introDuction
Screening programmes are public health initiatives to enable early detection – and 
usually treatment – of various medical conditions. This section will focus on newborn 
metabolic screening in New Zealand: the theoretical basis of population screening; 
the current screening programme; and what is possible or likely in the future from a 
scientific and clinical perspective.
Newborn screening per se is not limited to metabolic disorders: it includes any 
screening test performed on neonates, including for heart defects, deafness and 
hip dysplasia. The current newborn metabolic screening regime (often abbreviated 
to newborn screening) uses changes in the levels of normal blood compounds to 
indicate the possible presence of early onset, serious, treatable genetic disorders. 
New Zealand has recently increased the number of metabolic disorders on the 
newborn metabolic screening panel. New Zealand is following Australia and parts 
of the United States in the evolution and expansion of our newborn metabolic 
screening programme, so we have access to a great deal of international data to guide 
the development and improvement of our programme. Much has been written 
already on newborn metabolic screening internationally so, to prevent repetition, 
readers will be referred to some of these documents for more detail or a different 
perspective. 
This report will also examine the potential of direct genetic (DNA) screening 
of newborns, and its possible place in a future New Zealand newborn screening 
programme. DNA screening is currently not feasible in the public health context, 
although this may change as the technology improves and the costs reduce. In 
addition, interpretation of genetic information, unlike metabolic results, can be 
imprecise. The ability to understand the implications of particular genetic results will 
have to improve as well. Whilst both indirect (metabolic) and direct (DNA) newborn 
genetic screening have some benefits in common (early detection and treatment), 
DNA screening is thought to have wider implications – medical and in particular 
social – for the person undergoing testing.
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2  meDical screening Programmes
The object of screening for disease is to discover those among the apparently well 
who are in fact suffering from disease.3
2.1  screening is public health
Prevention is better than cure.
Screening programmes are public health measures. Public health focuses on 
populations, rather than individuals, and is typically the responsibility of government. 
It is in the public (and political) interest that as many people as possible are healthy 
and contributing to society. There is generally a limited budget with which to achieve 
this goal so spending is prioritised in favour of strategies that give the most health 
benefit for the cost. 
Encouragement of good population health can be approached in a number of ways. 
It may involve strategies such as prevention of illness, control or treatment of illness, 
physical aids to enable high function, environmental monitoring and accident 
prevention. 
Public health encompasses diverse areas of population health including (but not limited 
to) food safety, vaccination programmes, epidemic control, health inequities, safety 
and injury control, hygiene and sanitation control and screening for early detection 
and treatment of disease. The wide focus of population health potentially impacts 
on autonomy, liberty, privacy and property.4 In exceptional circumstances, public 
health can be and has been used to justify the restriction of all four of these individual 
aspects in serious risk situations, including detention and compulsory treatment for 
tuberculosis and closing (and prosecution of) unhygienic food premises.
As a public health initiative, medical screening has a fundamentally different basis from 
that of an individual medical investigation, although many of the testing techniques 
are the same. Investigative medical testing is prompted either by physical symptoms 
(i.e. it is diagnostic) or by a strong family history of a disorder, which suggests an 
increased likelihood of developing the disorder. Testing is personal medicine, for the 
benefit of the individual (and family); screening will have this effect ultimately, but it 
is aimed primarily at the good of a population. Any benefits resulting from screening 
are measured from the point of view of population health and include reduction of 
disease burden (incidence, morbidity and mortality) and the (eventual) reduction of 
national health costs from early detection and intervention.
Health screening involves testing ostensibly healthy people for a disorder that they 
may be unlikely ever to have (or pass on), in the hope of detecting the unlucky few 
who have or will develop it. Often, the screen is a simple indicative test and is a 
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springboard for more extensive testing to investigate and verify any positive result; that 
is, a diagnosis. Screening a healthy population imposes extra responsibilities on the 
programme that may not be relevant for more personal, diagnostic investigations.
Screening programmes aim to detect as many people as possible with a particular 
undiagnosed health issue, in the most cost-effective way and with the least number of 
negative implications (missed diagnoses, unnecessary investigation and/or treatment 
and psychological suffering). As a cost-reduction tool, a screening programme must 
reduce disease incidence, morbidity or mortality in a cost-efficient manner. 
Despite the population health perspective, however, there is a duty to minimise 
negative personal and/or social consequences for populations and the individual, 
particularly when there is little risk to others (as opposed to, for example, a deadly 
contagious disease). Criteria for a successful screening programme with respect to 
newborn metabolic screening, and the risks and responsibilities associated with such 
programmes, will be examined in this section.
Active national health screening programmes in New Zealand are BreastScreen 
Aotearoa (breast cancer), National Cervical Screening Programme (cervical 
cancer) and the Newborn Metabolic Screening Programme.5 Programmes under 
investigation or in the process of being implemented are universal newborn hearing 
screening, antenatal HIV screening, screening for chlamydia infection, colorectal 
cancer screening and antenatal screening for fetal aneuploidy.6
2.2  selective screening
The vast majority of screening programmes are selective or targeted in some way, 
rather than being mass or whole-population screening for serious disease. Some 
programmes are selective for particular age groups or developmental stages; others 
are selective for ethnicity or environmental factors. Population subgroups are selected 
on level of risk, based on epidemiological data.7 The higher the risk to a selected 
population, the more likely a programme is to be cost effective.
Breast cancer, for example, rarely develops in men and young women, so the targeted 
population for BreastScreen Aotearoa is women between the ages of forty-five 
and sixty-nine.8 This means that men and younger women who do develop breast 
cancer will be detected through other means and possibly with more advanced 
cancer. The cost of regularly screening the whole population would be prohibitively 
expensive, however, as well as being a drain on specialised personnel and equipment. 
Psychologically, it is also a source of worry for those people with false positive results 
who require follow-up screening. This latter group (false positives) is likely to be 
principally made up from the groups of men and younger women as, in women, 
younger breast tissue is often more difficult to screen accurately using current X-ray 
20
technologies.9 Limiting the population screened to those who are most likely to have 
detectable cancer constitutes the balance between coverage and cost efficiency. This 
does not mean that people with a known higher risk of breast cancer are excluded 
from screening entirely; merely that they may not be included in a formal population 
screening programme.
In New Zealand, some ethnic populations also have higher incidence of and death 
from breast cancer, whether through inherited genetic susceptibilities, environmental 
factors or late detection (often because of delayed reporting of symptoms).10 
Advertising campaigns and other mechanisms target susceptible populations, in the 
hopes of further lowering the breast cancer morbidity and mortality rates in these 
populations and therefore overall.
The newborn metabolic screening programme, by contrast, consists of a one-off test: 
screening for multiple conditions that have serious (life-threatening) consequences 
for newborns and young infants. Newborn screening is, on one level, a mass-screening 
programme as every individual newborn is offered screening and, ultimately, most of 
the population will be screened. It is also a time when almost every child will be in 
contact with medical personnel. As such, it represents a convenient opportunity for 
screening for slightly later onset (months rather than weeks) disorders, in addition to 
disorders with very early onset.
A selective aspect of the newborn screening programme is that the disorders 
currently on the screening panel manifest initially at this very early stage in life, with 
identifiable signs around day two after birth, and are most effectively treated early. 
Later onset disorders (e.g. Duchenne muscular dystrophy (DMD)) are not currently 
considered for the screening panel, as they can be detected later in the child’s life or 
are currently untreatable. Newborns in New Zealand are screened for hip dysplasia, 
heart defects and a number of metabolic, endocrine and exocrine disorders. Hearing 
testing will soon be introduced in the whole of New Zealand.
All newborns in New Zealand are tested with the same metabolic screening panel, 
although this is not necessarily the case overseas. Until recently, testing for sickle-
cell anaemia and thalassaemia in the United Kingdom was restricted to particular 
ethnicities with a higher incidence of these disorders, although screening is shortly to 
become available to all newborns.11
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  newBorn metaBolic screening Programmes
… early diagnosis is better than diagnosis made late in the natural course of a 
disease process.12
.1  what is newborn metabolic screening?
A brief summary of all the disorders included in the New Zealand newborn metabolic 
screening programme is available on the National Screening Unit website.13 For more 
information on individual disorders, see National Newborn Screening and Genetics 
Resource Center,14 the March of Dimes website15 or the Financial, Ethical, Legal 
and Social Issues website.16 For extensive descriptions of the various disorders, see 
‘Newborn Screening Fact Sheets’,17 published by the American Academy of Pediatrics 
and the ACMG report on standardising newborn screening.18 
Newborn metabolic screening is a public health programme in which the majority 
of newborns are screened for a select group of early-onset, severe and (currently) 
treatable disorders. Four blood spots (from a heel prick) are taken at approximately 
forty-eight hours after birth. These blood spots are sent to a testing facility, where 
small circles of the dried blood samples are punched out and analysed for various 
chemical compounds in the blood. Particular biological molecules, where found at 
unexpected concentrations (whether too high or too low), can indicate a disorder. An 
abnormal screening result is followed up with more precise testing to reach a more 
conclusive diagnosis.
Metabolic refers to the process of digesting food into smaller chemical compounds 
(metabolites) that the body can use for energy and for growth. Protein catalysts called 
enzymes, which are encoded in DNA by genes, produce metabolites by breaking down 
food. If an enzyme for breaking food into reuseable components is faulty or absent, 
because of a harmful genetic mutation, then a metabolic disorder can result. Symptoms 
may be because of a deficiency in or toxic accumulation of a particular metabolite. 
There are three main groups of metabolic disorders relating to dietary protein and 
fat digestion: amino acid, organic acid and fatty acid disorders respectively. For this 
reason, a variety of metabolites can be used as a measure of ‘normal’ metabolism. 
For the metabolites measured in newborn screening, the ‘normal’ or healthy 
concentration ranges are known for each particular disorder and newborns with a 
result outside this range are investigated further. 
As metabolic disorders relate to food processing, many of the health effects can 
be ameliorated and even eliminated through modification or supplementation of 
diet. In phenylketonuria, for example, a liver enzyme involved in the processing of 
the amino acid phenylalanine is non-functional. By almost completely removing 
20
phenylalanine from the diet, the severe health effects of the disorder (developmental 
delay, seizures, speech abnormalities) can be greatly reduced, although there are still 
some residual effects. 
The phrase newborn metabolic screening is slightly misleading, as it is not solely 
metabolic disorders that are screened for. Whilst metabolic disorders comprise the 
majority of disorders in the panel (particularly in the recently introduced expanded 
screening), two endocrine disorders19 (congenital hypothyroidism and congenital 
adrenal hyperplasia) and an exocrine20 disorder (cystic fibrosis) are also commonly 
included. 
In the case of endocrine disorders, missing hormones that would normally be 
produced by the body can be used as the treatment. There is no treatment to eliminate 
all the symptoms of the exocrine disorder, cystic fibrosis; although antibiotics and 
physiotherapy are used to try to prevent infection and move thickened mucus in the 
lungs. Secreted pancreatic enzymes can be replaced in the form of pills and attention 
to and supplementation of diet can reduce growth impairment and malnourishment 
often seen in children with cystic fibrosis. This treatment can improve quality of life 
and extend the lifespan of an affected person through to their thirties or even forties.
.2  newborn metabolic screening is genetic screening
Genetic testing is not strictly limited to DNA-based analysis. Any test that can indicate 
a genetic disorder is generally termed a genetic test. In this way, newborn metabolic 
screening is genetic screening, although no DNA is examined directly in the initial 
screen. To avoid confusion and differentiate between direct genetic screening and 
(non-DNA) metabolic screening, genetic testing through direct interpretation of DNA 
sequence will be referred to as DNA testing or screening throughout this report.
Virtually all the disorders on the metabolic newborn screening panels internationally 
are autosomal recessive genetic disorders. Both parents must contribute a non-
functional copy of the (same) gene to give rise to an affected child. In cystic fibrosis, 
for example, an affected child will have two non-functional copies of the CFTR gene, 
one inherited from the mother and one inherited from the father. 
Some non-functional gene versions (alleles) are more common in certain populations 
than others. In populations of Northern European origin (often called Caucasian), 
non-functional CFTR gene alleles are more common than in other (e.g. Asian) 
populations. This higher frequency in a population increases the chance of both 
parents being carriers (i.e. both have one functional and one non-functional copy of 
the particular gene). A carrier couple has a one in four chance of having an affected 
child. If the non-functional alleles of genes are very rare, then the chance of both 
parents being carriers is very small, unless they are related to one another. 
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Most metabolic disorders are very rare because the non-functional alleles are rare 
in the population. The more common non-functional alleles, for example in cystic 
fibrosis, may have some evolutionary advantage when present in a single copy (i.e., 
in a carrier), although the actual advantage conferred by a non-functional CF allele 
is unknown.
Other disorders have a genetic basis but are often de novo (new) mutations rather than 
inherited. Congenital hypothyroidism is most commonly a sporadic (non-inherited) 
endocrine condition. Approximately 15 per cent of occurrences are thought to be 
genetic21 but the overwhelming cause is thought to be thyroid dysgenesis (failure 
to develop normally). This is an error of early development, as identical twins are 
mostly not both affected;22 but it is difficult to estimate the genetic component of 
thyroid dysgenesis.23
DNA testing of individuals may be used, once the metabolic test results are confirmed, 
to ascertain the diagnosis or cause. Testing enables future family planning by the parents 
and wider family – in particular, in New Zealand, for the relatively common and well-
characterised disorder, cystic fibrosis. Testing may also have a research benefit. DNA 
screening is not currently in use in newborn programmes as the initial screen.
The fact that newborn metabolic screening is genetic screening has implications for 
the screening criteria that have not been recognised until recently – in particular, 
the implications for the wider family. This is discussed further in the fourth section, 
‘Criteria for the newborn screening panel’.
. newborn screening is symptomatic screening
Whilst newborn metabolic screening involves testing apparently healthy newborns, 
the screen is actually for an existing disorder. Although there are usually no obvious 
physical symptoms at that early stage in life, there is an existing, detectable phenotype 
by the time the blood sample is taken: the altered level of the key metabolite or 
hormone in the blood. All metabolic testing is symptomatic screening based on the 
blood screen.
This is in sharp contrast to DNA testing, where the presence of a disease-causing allele 
(or two) is only predictive of the development of a disorder. DNA analysis can give 
a numerical risk that the disorder will develop (this may be high or low depending 
on the disorder) and may give an indication of the severity of the disorder that does 
manifest. As we will see later in this section, however, there are no guarantees that 
DNA results predictive of disease will translate into a severe health disorder. There are 
currently no official nationwide newborn DNA screening programmes. Additional 
reasons for this will be discussed later in this report.
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.  a brief history of metabolic screening
In 1934, Følling published his discovery that phenylketonuria (PKU) was likely to be 
caused by an ‘anomaly’, probably related to the metabolism of a protein component 
(amino acid) phenylalanine.24 This led to the idea that dietary restriction could 
reduce the severity of PKU.25 Development of commercial diets for those children 
with PKU was well underway by the late 1950s.26 Unfortunately, PKU was often not 
detected until severe neurological damage was already evident in at least one child in 
affected families. 
A test developed by microbiologist Robert Guthrie and Ada Susi, and eventually 
published in 1963, was an early reliable test for PKU. It was also a revolutionary 
method of collecting the blood sample for testing: the blood was spotted onto filter 
paper and allowed to dry. The test itself was a bacterial growth assay, whereby dried 
blood spot samples containing elevated levels of the amino acid phenylalanine (an 
indication of PKU) promoted bacterial growth on selection media.27 Those with 
‘normal’ levels of phenylalanine did not allow growth of the bacteria (inhibition). 
The development of a reliable test meant that treatment, i.e. dietary restriction, could 
begin early, minimising the neurological damage characteristic of the disorder.
Less than 1 per cent of residents in United States institutions for intellectual 
impairments were known to have PKU at this time, although universal screening 
was promoted as a way of significantly reducing developmental delay and mental 
retardation in the population.28 The first infant affected with PKU was detected in 
New York State in 1962, after only 800 screening tests had been performed.29 This 
early find, other early successes30 and vigorous promotion compelled more and more 
States to introduce newborn testing and many made it mandatory. Newborn testing 
slowly spread internationally and new tests were added to what become a screening 
panel for newborns. The bacterial inhibition assay is no longer in use, as new 
technologies have improved detection sensitivities and replaced older methods. The 
cards used to collect newborn blood spots are still often called Guthrie cards, and the 
cotton-based ‘paper’ card technology has changed little since first developed.
.  modern newborn metabolic screening programmes
Newborn metabolic screening programmes vary from country to country and, 
in some countries, from State to State. There is a wide variation in programmes 
internationally, ranging from no screening in many developing nations, through to 
forty-five specific tests offered by New York State in the United States.31
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3.5.1.  International programmes
3.5.1.1  The United Kingdom (UK)
There is substantial and more detailed information available on the United Kingdom 
newborn screening programme website.32 The United Kingdom programme, formed 
in 2002, is accountable to the Department of Health and reports to the National 
Screening Committee. Screening is funded by the National Health Service (NHS) 
and currently covers approximately 600 000 newborns per annum. Parental consent 
is required for newborn screening.33
The United Kingdom currently only screens for two disorders universally: PKU and 
congenital hypothyroidism. Sickle-cell anaemia and thalassaemia have recently been 
added to the universal screening panel, although non-selective screening has yet 
to begin. These two groups of haemoglobin disorders are more common in those 
of African and Caribbean descent and, until recently, were only offered to these 
ethnicities. Now, because of intermarriage etc., [i]t is no longer possible to assume 
who may or may not be affected’.34
Cystic fibrosis (CF) screening is currently offered in some NHS trust areas and 
not others. Universal CF screening is being rolled out across the country and the 
newborn screening programme aims for screening to be offered ‘to all babies born 
in England by April 2007’.35 It is already available to those in Scotland, Wales and 
Northern Ireland.36 
Aside from a negative report in 1997,37 the United Kingdom did not appear to be 
contemplating expanding its screening programme, 38 despite there being possible 
justification for the use of tandem mass spectrometry to screen for glutaric aciduria 
type 1 (GA1), based on its own evidence.39 This was also true of medium-chain acyl 
CoA dehydrogenase (MCAD) deficiency, but the screening programme recently 
announced its addition to the newborn screening panel.40 
3.5.1.2  Australia
Screening in Australia is fully publicly funded and parental consent is required for 
participation. ‘[A]pproximately 258,000 newborn screening cards are processed in 
Australian laboratories’ every year.41
Screening in Australia is superficially dictated and performed State by State (under 
State health departments), although there is a degree of co-ordination between the 
centres. There are five principal screening laboratories: ‘… Western Australia (WA), 
South Australia (SA) that also covers Tasmania (TAS) and part of the Northern 
Territory (NT); Victoria (VIC); New South Wales (NSW) that also covers the 
Australian Capital Territory (ACT) and Queensland covering part of the Northern 
Territory.’ 42 All centres had adopted tandem mass spectroscopy (MSMS) screening by 
2004, with WA being the final State to implement extended screening.43
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State newborn screening is based upon and guided by national and Australasian 
policies, for example the joint Human Genetics Society of Australasia (HGSA) and 
Royal Australasian College of Physicians (RACP) policy statements.44 As such, New 
Zealand and Australian screening programmes are now aligned and there is co-
operation between the programmes.
Each State decides a number of operational aspects.45 Whilst the latest HGSA/RACP 
guidelines suggest a number of disorders that States could choose to include in State 
screening panels, the programmes are now ‘essentially aligned’.46 To facilitate a more 
standardised programme in other operational areas (such as retention of Guthrie 
cards), the Australian Health Minister’s Advisory Council (AHMAC) Advisory Group 
on Human Gene Patents and Genetic Testing has recently undertaken a consultation 
on what this standardised programme might look like.47
3.5.1.3  The United States of America (US)
Screening programmes are run at the State level in the US. Programmes vary 
enormously from State to State, at all levels. Funding is from a variety of sources: it 
usually comprises varying combinations of State, insurance and ‘user pays’. Screening 
is compulsory in most States (48/51) so consent is often not sought and the level of 
information provided to parents is variable.48 Some States have opt-out clauses ‘for 
(1) religious reasons (33/51), (2) any reason (13/51)’.49 Almost four million newborns 
are screened per annum.50
There is a move in the US to standardise the screening tests available in each State, 
and to upgrade all screening programmes to tandem mass spectrometry. This move 
is led by the Department of Health, which commissioned an American College of 
Medical Genetics analysis.51 The ACMG report recommends a core-screening panel 
of twenty-nine disorders through the widespread introduction of MSMS screening. 
The State-based funding of newborn screening programmes compromises this 
initiative, due to different levels of funding and support, and there is therefore a push 
to introduce at least partial federal funding of these programmes.
3.5.2  New Zealand 
Screening was established in New Zealand in the mid-1960s. Guthrie took sabbatical 
leave to Dunedin, New Zealand in 1968 and Professor Arthur Veale started up 
newborn screening from the Otago School of Medicine as a result. The programme 
was moved in 1973, when he moved to the new medical school in Auckland.52 
The National Screening Unit (NSU) now oversees and is responsible for the newborn 
metabolic screening programme, from within the Ministry of Health.53 This chain 
of responsibility is a relatively recent occurrence.54 The NSU contracts the Auckland 
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District Health Board and its medical testing laboratory LabPLUS to provide the 
newborn screening services.55
The Starship Foundation (a national children’s health charity) recently gifted the funds 
for a Tandem Mass Spectrometer (MSMS) to the Auckland District Health Board, 
to enable expanded screening in New Zealand. The screening panel was extended 
from seven disorders to approximately twenty-nine disorders (depending how they 
are classified) and extended screening began on 1 December 2006. The disorders 
on the New Zealand screening panel are described and summarised by the NSU.56 
Phenylketonuria (PKU) and maple syrup urine disease (MSUD) screening has been 
transferred to the MSMS; the other individual tests continue to be performed using 
existing technologies. The disorders on the panel are now aligned with Australia. 
Extended screening is estimated to be able to detect five to ten more affected infants 
per year, in addition to the approximately thirty-five newborns already identified 
annually.57 It can be estimated that approximately one in 1500 New Zealand children 
is affected by one of the seven disorders on the original panel.58
New Zealand has an extremely high rate of coverage in screening newborns, 
estimated by the newborn metabolic screening programme to be between 99 and 
100 per cent of the approximately 59 000 or more children born annually.59 Informed 
consent by parents is required, although anecdotal evidence is that the informed part 
of the consent process is not occurring consistently. There is also recent evidence 
from Australia showing a low level of knowledge of the programme, even amongst 
parents.60 The New Zealand situation is likely to be similar. (See the section in this 
Report by Kirsty Dobbs and Richman Wee, ‘Newborn Screening and Related Legal 
Issues’, for further discussion regarding parental consent.)
There are various reasons for the success of the New Zealand programme, not least of 
which is the commitment of the staff. New Zealand has a small population with a State-
funded, central testing laboratory. The publicly funded health system also supports the 
follow-up testing and treatment of affected children. Being small allows New Zealand 
the flexibility to modify the programme quickly as new evidence and best practice is 
reported; although the small size (and level of funding) also makes it more difficult to 
innovate in the way that some larger countries do. Additionally there is a mandated 
single point of contact for each newborn in New Zealand, the Lead Maternity Carer 
(LMC), which allows for efficient follow-up and retesting if required.
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  criteria For the newBorn screening Panel
In 1968, a set of principles was published under the auspices of the World Health 
Organisation to guide screening programmes (Box 1). This early set of criteria, proposed 
by Wilson and Jungner, was aimed at ‘… the chronic non-communicable diseases 
prevalent in the more advanced countries …’61 – such as adult-onset cancer – so some 
aspects are not necessarily applicable to newborn screening. These principles are still 
in general use today, however, although there are many variations on the theme. Some 
precepts appear to be more universal than others and all are, to some extent, subjective.
Box 1: wilson-Jungner principles of early disease detection2
1. The condition sought should be an important health problem.
2. There should be an accepted treatment for patients with recognized disease.
3. Facilities for diagnosis and treatment should be available.
4. There should be a recognizable latent or early symptomatic stage.
5. There should be a suitable test or examination.
6. The test should be acceptable to the population.
7. The natural history of the condition, including development from latent to   
 declared disease, should be adequately understood.
8. There should be an agreed policy on whom to treat as patients.
9. The total cost of case-finding (including diagnosis and treatment of patients   
 diagnosed) should be economically balanced in relation to possible    
 expenditure on medical care as a whole.
10. case-finding should be a continuous process, not a ‘once and for all’ project.
Most programmes now state the criteria on which they (claim to) have been based. 
In the main these criteria draw heavily on the Wilson-Jungner principles, including 
those of the National Screening Unit in New Zealand (again these were written with 
adult-onset cancers in mind, not newborn screening).63 Another criterion that has 
been added subsequently is a requirement for evidence of effectiveness, although this 
is possibly implicit in the original principles. New Zealand also requires ‘consideration 
of social and ethical issues’, which presumably includes such issues as education and 
consent, although this is unclear.64
As more disorders are added to newborn screening panels through improvements in 
technology, the threshold for inclusion appears to be evolving, and the older criteria 
are being modifyied or challenged. In the case of ‘acceptable treatment’, for example, 
there is much discussion (and seemingly less published research)65 about the efficacy 
of some treatments in preventing health crises and providing benefits to the child. 
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The benefit to populations and affected individuals is larger and varied. Affected 
individuals with non-treatable disorders can still benefit from newborn screening. 
However benefits are mostly indirect (i.e. to the family unit rather than medically 
to the individual), and may be accompanied by (somewhat intangible) harms of 
varying magnitude, such as stress, anxiety and changes in behaviour.
Various commentators are starting to challenge aspects of the Wilson-Jungner criteria 
for newborn screening. Wilcken, who has gone the farthest, attempts to reformulate 
the criteria into something more suited to the heterogeneity of newborn screening 
programmes. Wilcken66 has gone back to first principles to examine the older criteria, 
looking at four broad principles: beneficence, non-maleficence, autonomy and 
justice. She concludes that, in the absence of harm, screening may be beneficial even 
when there is no direct benefit to the newborn.
This section will loosely examine some of these principles as well as more scientific 
aspects in relation to modern newborn metabolic screening.
.1  Prevalence and severity of disorder
Wilson and Jungner specify that the condition should be an ‘important’ health disorder 
– a subjective criterion. Importance will vary depending on the point of view (personal, 
family, community, health system, economic) from which this criterion is assessed.
An unusual feature of newborn metabolic screening is that the individual disorders 
are rare across the population and the number of children affected by a single 
disorder can be as low as one in 100 000 newborns or less. The combined detection 
rate for the whole screening panel is, however, comparatively high (one in 1500 in 
New Zealand using the old screening panel).67 Testing for a number of rare disorders 
increases the number of children who are helped significantly, thereby increasing 
the benefit to society. The principal advantage of newer screening methodologies 
is that very rare disorders are easily added to the screening panel, at little extra cost, 
providing incremental benefits to population health and a significant benefit to those 
few children and families affected.
Individual benefit from screening is small because of the rarity of these disorders 
(although, when combined, they become much less rare). On this basis, parents can 
seemingly opt out with relatively little risk. Some justify opting out of the scheme 
on the basis that their child’s pain, from obtaining the blood sample, outweighs any 
benefit from screening.68 It has been estimated, however, that a 1 per cent drop in 
screening coverage in Australia would result in ‘… two or three babies per year with 
a treatable disorder [who] could die or suffer permanent damage’.69 
The severity of the disorder to be screened for must be considered; the more severe 
the disorder, the greater the cost benefit ratio to the child and society. This criterion 
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is subjective and more relevant where individual tests are performed, as opposed 
to expanded screening where an additional metabolite is easily examined in a two-
minute screen. If a disorder is not considered ‘important’70 as far as childhood 
health goes, but can be definitely and cheaply detected and treated, then it still may 
be considered for inclusion on the panel. This has not yet occurred in metabolic 
screening and newborn screening panels comprise only serious (often lethal), very 
early onset disorders.
Prevalence can also affect the validity of a screening test through its ‘positive predictive 
value’. This is discussed more fully in section 4.2, ‘Valid screening test’.
.2  valid screening test
This criterion is one of the most important and underlies the whole basis of 
screening. Without an effective screening test, extra cost is incurred as well as possible 
psychological harm to parents whilst a large number of families wait for confirmation 
of a positive screening result, which may turn out to be a false positive. Alternatively 
(or additionally), a number of affected children may not be identified from the screen, 
losing the opportunity for early treatment and, consequently, public confidence. 
The validity of a test can be defined by two concepts: sensitivity and specificity. 
Sensitivity is the ability to identify accurately all those children affected by a particular 
disorder (true positives). Specificity is the ability to identify accurately all those child 
not affected by a particular disorder (true negatives). With most newborn screening 
tests, as with any other, there is often a trade-off between sensitivity and specificity: 
the more affected children that are detected, the more unaffected children that return 
a false positive screening result.
Testing for chemical compounds in a blood sample rarely yields a simple yes or 
no answer. In a group of healthy people, the molecule of interest will be present in 
a variety of concentrations, known as a normal range. These concentrations may 
even change within an individual, on a daily or even hourly basis. If the molecule 
is at a concentration within the normal range, it is likely (but not certain) that the 
individual will be healthy. If the level of the compound is outside the normal range, 
this could (but not definitely) indicate a disorder.
The problems with balancing sensitivity and specificity can be illustrated using a 
theoretical example as in Figure 2. The average concentration for unaffected people 
is approximately 5 units and approximately 8 units for affected people. Until the 
graph is examined, this initially seems sufficiently different to enable diagnosis. 
Unaffected people may have a blood concentration of the compound ranging 
from approximately 2.75 to 7.25 units. Affected people may be in the range from 
approximately 4.5 to 11.25 units. As can be seen, the affected and unaffected ranges 
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overlap, so if a screening test gives a result of 6 units, additional tests must be done 
to try and determine disease status. If the result is 10 units, then it is very likely that 
the individual is affected, as there were no unaffected people with this concentration 
in the population.
In a screening test, a cut-off point is used, below or above which there will be further 
investigation. If point A (6 units or more) is used then most affected people will be 
followed up, but a proportion of unaffected people will also be investigated (high 
sensitivity, low specificity). If point B (6.5 units or more) is used, then a lot of affected 
people and fewer unaffected people will be investigated (lower sensitivity, higher 
specificity). If point C is used (7 units or more), then up to a quarter of affected 
people will be missed, but almost no unaffected people will be investigated (low 
sensitivity, high specificity).
Figure 2: The results of a hypothetical screen and the balance between sensitivity and 
specificity.
The chemical compound of interest (test variable) can be detected in overlapping ranges 
in unaffected and affected individuals. The Y axis (not shown) is number of people. A, 
B and C are three potential cut off points for further investigation, each with differing 
specificities and sensitivities. 
Source: Wald and Leck, 200071
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The cut-off value used depends on how important it is to identify affected newborns. 
For a disorder such as PKU, where early identification and treatment are crucial 
to a good outcome, the cut-off point may be set to capture more newborns (more 
false positives) than a disorder such as cystic fibrosis, where children are sometimes 
identified at birth (outside the screening process) and where prophylactic treatment 
is helpful, but not crucial to a good outcome.
One result of the large crossover between healthy and affected, for cystic fibrosis 
testing in particular, is that unaffected carriers (with one functional copy and 
one non-functional copy of the CFTR gene) may be detected in the affected range. 
Carrier detection in itself is relatively harmless,72 as there is no actual disease present, 
but may cause distress to parents, particularly when the concept of ‘carrier’ is 
misunderstood. Parents and relatives who may also be carriers should subsequently 
be offered testing for carrier status, to discover whether there is a risk to future 
children of actual cystic fibrosis.
By themselves, however, sensitivity and specificity are not enough to ensure an 
acceptable screening test, and an effective diagnostic test may not necessarily be an 
effective screening test. A calculation called positive predictive value can take into 
account sensitivity and specificity, and the overall prevalence of a disorder in a 
population.73 Positive predictive value is a measure of the probability that someone 
with a positive result for a disorder is actually affected. Conversely, negative predictive 
value gives a measure of the proportion of people with negative test results who do 
not have the disorder.
The more common a disorder is in a population, the more favourable is the positive 
predictive value. Positive predictive value also changes from one population to another. 
Hence, even with a good, reliable screen, if the disorder is rare in a population, there 
will be a higher number of false positive results than true positives. This factor must be 
taken into account when managing follow-up services for those with positive tests.
Whilst sensitivity, specificity and positive predictive value are crucial, a number of 
other factors are also important. To be useful as a population screen, a test must be 
simple, reliable and consistent, easily automated and inexpensive.
.  treatment: is this necessary for screening?
The availability of an efficacious treatment is a now a contentious criterion for 
inclusion of a disorder in a screening panel. The disorders screened for in New 
Zealand, for now, are ‘treatable’. Wilson and Jungner’s original criteria suggested 
treatment was necessary for inclusion and, indeed, they state that it is probably the 
most important criterion.74 Whilst treatment is an important aspect of newborn 
screening, nevertheless there is still value in very early detection of a disorder in the 
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absence of a treatment, from the points of view of the child, the family and public 
health. This is not necessarily the case with the chronic disorders that Wilson and 
Jungner had in mind, although lifestyle planning is still a relevant factor for those 
with chronic adult diseases.
The definition of ‘accepted treatment’75 does not necessarily mean that the treatment 
is cost effective (in a public health context), widely available or even particularly 
efficacious; it is just the best treatment available, preferably with minimal side effects. 
Treatment is, in the main, not a permanent cure in the context of inherited newborn 
metabolic disorders. The ease and cost of treatment vary enormously depending 
on the severity of the disorder and the efficacy of treatment, which may mitigate 
a few, some, many or all symptoms. Treatment can range from simply avoiding 
fasting (e.g. medium-chain acyl-CoA dehydrogenase deficiency (MCAD)), dietary 
supplementation (e.g. biotinidase deficiency) or severe dietary restriction (e.g. PKU) 
to, more extremely, a liver transplant (e.g. methylmalonic academia), a heart and 
lung transplant or gene therapy (e.g. cystic fibrosis or CF). 
The severe dietary restriction of phenylalanine that is the treatment for PKU, whilst 
very effective, is costly (if it is not State funded, as in the United States) and onerous 
for those on the diet. Even at the risk of severe neurological symptoms, a number of 
teens fail to maintain the strict diet required.76 
The principal benefit of early detection, in the absence of treatment, is knowledge. An 
early diagnosis has a benefit to the newborn child, as it saves the so-called ‘diagnostic 
odyssey’. This ‘odyssey’ is the process of wondering, waiting for medical consultations, 
examinations and testing to identify the cause of physical symptoms in an ill child. 
Whilst testing may be as innocuous as an additional blood sample, it can also be 
invasive and painful, depending on the tests required. It may also involve a series of 
tests over a long period. Some of these tests will still be required to confirm disorders 
detected through newborn screening but there are likely to be fewer tests if there is a 
specific disorder in mind. 
Knowledge saves clinician time and health dollars in quickly diagnosing rare disorders, 
and may mitigate some of the worry for parents around an undiagnosed, inexplicably 
ill child. Some disorders are notoriously difficult to identify in the early stages and 
Duchenne muscular dystrophy (DMD), for example, may take up to two years from 
first symptoms to diagnosis.77 As such, affected families tend to come out in favour of 
early diagnosis through screening rather than a wait-and-see approach.78
Disorders in newborn screening programmes typically are rare autosomal recessive 
conditions and, as such, there is usually no awareness of the disorder in the family 
until an affected child is born. Knowledge of the potential for a specific, severe genetic 
disorder in a family gives options for future family planning and testing of older 
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siblings (who potentially may be mildly affected or undetected). Family planning 
may (or may not) include reproductive planning (no more biological children, 
preimplantation genetic diagnosis or prenatal testing of future pregnancies). This 
may have indirect implications for the affected child in that an additional affected 
sibling may cause financial and/or emotional strain on a family, which in turn impacts 
on the child. Family planning also includes options regarding where and how to live, 
such as moving closer to support and medical services, a house with no stairs when 
there are mobility issues, special education options for the child, financial savings for 
future care and estate planning.
Wilcken79 and others have argued that benefit to the family and absence of harm 
to the child still constitute grounds for testing newborns for disorders with no 
treatment, in some instances. Others argue that only direct benefit to the child in 
the form of treatment is appropriate,80 as consent is not by the individual, but by the 
parent for the benefit of the child. This argument is more pertinent for later-onset 
disorders than for these very early to early onset, severe disorders that are already 
manifesting in some way. Issues that have been raised include problems bonding 
with a well but already diagnosed child, anxiety and stress, medicalisation of lifestyle 
and using untested, unproven and potentially expensive alternative therapies. There 
is also a risk of treating the child differently from the child’s siblings; although this 
is not necessarily a negative, and benefits from a change in parental attitude (e.g. 
greater appreciation of all of their children) may flow through the whole family.81 
Nonetheless, there is much supposition and little evidence in this area.
The Human Genetics Society of Australasia (HGSA) policy statement (2004) on 
newborn screening makes no specific mention of treatment as a necessary criterion. 
There are, however, a few oblique (and contradictory) references to treatment:82 
Timely intervention in these disorders significantly reduces morbidity, mortality 
and associated disabilities.
1.1 There is benefit for the baby from early diagnosis (benefit to the family may  
 also benefit the baby).
There is a comment at the end of the document to the effect that screening for a 
number of (untreatable) disorders was not currently recommended, one of the 
reasons being ‘proof of advantage from early diagnosis is absent or uncertain’.83
In the United States, where testing is often mandatory, testing for untreatable disorders 
can be interpreted as a problematic situation. This is because parents are, in some 
States, not given the choice of whether to screen or not. Whilst this may be thought to 
be appropriate for the current screening panel, some parents may not wish to know 
certain information if there is no direct action that they can take. Testing without 
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informed consent is neither appropriate nor current clinical practice, particularly for 
predictive testing of later-onset disorders. 
In countries such as New Zealand, where informed consent is required, there may be 
fewer ethical and social issues regarding screening for untreatable disorders. Those 
who have an objection to screening for untreatable or later-onset disorders have the 
right to refuse in New Zealand, in accordance with standard genetic testing practices. 
This in turn means that their children will not be screened for treatable disorders, 
should they be added to the screening panel in the future. One option to diffuse 
this situation could be separate consent sections for ‘treatable’ and ‘non-treatable’ 
disorders. Education and informed consent also play a key role in the potential 
introduction of screening for untreatable disorders.
Parents with such knowledge could choose to use prenatal or preimplantation genetic 
testing in any future pregnancies or alternatives such as gamete donors or adoption, 
or could choose not to extend their biological family. Obviously, use of the above 
technologies should never be compulsory but, even if only a few parents choose to 
prevent a future affected birth, through whatever method, then there is some public 
health benefit. 
As newborn screening is additionally for the benefit of the population and public 
health, it could be argued that any improvement to public health is a desirable aspect 
of newborn screening. This definition would include the potential for reduction 
of future affected births. Compulsion in testing and, more particularly, future 
reproductive planning is known as eugenics and is undesirable. Giving parents a 
choice and, potentially, options for future decisions is not eugenics.
There is little extra initial cost to adding more disorders to MSMS screening. Any 
cost is in follow-up and confirmation of diagnosis. If a test is discriminating enough 
then this cost should (intuitively) be less than later diagnosis. Whilst there is little 
direct benefit to the newborn (except avoiding many medical tests), there is greater 
benefit to the family as they know what to expect and can make reproductive and 
lifestyle decisions. There is a possible benefit to society in reduced numbers of tests 
and clinician time used for diagnosis, as well as a potential benefit if parents actively 
choose to avoid another affected birth.
Some have argued that parental or couples screening is a more logical approach 
if family planning options are an intended outcome of screening for untreatable 
disorders. This may be true but there are also arguments against this timing,84 not 
least of which is the number of de novo mutations that occur during egg, sperm 
and/or embryo formation that would not be detected. One third of children born 
with Duchenne muscular dystrophy, for example, are a result of de novo mutations 
in the egg or embryo. Other arguments against parental screening include the lack 
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of planning in many pregnancies and the current difficulty in screening for one 
disorder, let alone many rare disorders.
. characterisation of disorders
It is important to have a thorough understanding of the natural history of disorders 
on any screening panel. Some disorders appear to be similar but in fact have differing 
causes, requiring different treatments. Information on the natural variability of 
disorders can also lead to a significant amount of information on the effectiveness 
of the various treatments. Ironically, some of this information may actually only 
be gained in the practice of screening, principally due to the rarity of many of the 
disorders. 
Phenylketonuria (PKU) is the result of mutations to the phenylalanine hydroxylase 
(PAH) gene. It eventually became clear that, in a small percentage of cases, high levels 
of phenylalanine in the blood did not always mean that the child had PKU and that 
these children did not respond well to dietary restriction.85 Approximately 1 per cent 
of high phenylalanine blood levels were the result of non-PAH mutations that affect 
how another factor participates in the phenylalanine-processing chain. Infants with 
perturbations in the levels of this tetrahydrobiopterin factor (BH4) have similar 
symptoms to PKU but do not response to the dietary restriction in the same way 
as newborns with classical PKU do. In fact, the severity of the dietary restriction 
actually caused substantial harm. PKU screening also detected mild variations of the 
disorder, where treatment may not be necessary at all and again could cause more 
harm than good.
The example of PKU illustrates the importance of a thorough understanding of the 
disorder in question. Due to the rarity of some of these disorders, however, it is difficult 
to gain this sort of detailed knowledge before the advent of a screening programme, 
because of the problems with diagnosing some of these affected children. Specialist 
research programmes and patient support groups have an important role to play in this 
aspect of screening programmes, through identifying affected families and carrying 
out more detailed research than can be undertaken by a screening programme.
. cost/benefit
Cost/benefit studies typically have not been very comprehensive in the past and are 
often based on direct costs to the screening programme. There are many costs, some 
of which are indirect and difficult to measure. Examples of costs include: population/
parent education; the actual test (which can be further broken down into personnel, 
equipment purchase and maintenance, materials, overheads etc.); interpretation of 
ambiguous results by metabolic specialists; retesting or more specific confirmatory 
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testing for diagnosis of both affected and false positive samples; consequent testing of 
close family members; clinical management by metabolic specialists; direct treatment 
costs; and genetic counselling. These costs may or may not be offset by the early 
detection and treatment of affected children, and require careful evaluation.
Benefits include: reduced costs to the health system in hospital emergency 
departments; effective diagnostic processes; lower care needs (paid and unpaid) in 
disorders with developmental delay that can be prevented (including education); and 
ability to contribute to society and the economy.
Some costs and benefits, however, are more intangible and harder to put a monetary 
value on. Costs of this type include increased parental stress and time spent with 
children in medical clinics (both with and without screening). Benefits may include 
prevention of death of a child; informed decisions regarding future family plans; and 
lowered anxiety from early understanding of a condition.
One way to regard screening, given the difficulty of pricing a life, is in terms of 
effectiveness86 and hence as a justifiable cost to the health system. It is obviously more 
difficult to justify in a health system such as that of the United States because of the 
strong cost drivers from an insurance-run structure.
  the screening technologies
No one technology can as yet cover all the disorders screened for in newborns. 
In centres using older technologies, each disorder is tested for individually, using 
the most appropriate specific test. The newer tandem mass spectroscopy (MSMS) 
technology enables simultaneous, high throughput testing of many metabolites. Not 
all disorders are detectable with MSMS technology so some disorders will continue 
to be tested for individually, even in expanded screening programmes. In New 
Zealand, only two tests from the old screening panel have been moved to the MSMS 
platform: phenylketouria (PKU) and maple syrup urine disease (MSUD). The other 
five remain as individual tests.
.1  Biochemistry and immunohistochemistry
Biochemical and immunohistochemical testing are established technologies in 
newborn screening. As each test is for a specific molecule or protein, a new test must 
be developed for each new disorder to be screened for.
Biochemical testing involves testing the level of activity of a specific enzyme in a 
sample. Enzymes convert (catalyse) one molecule into another. Even if an enzyme 
is being made in the body, if it is not active, then the sample will give a positive test 
result for a disorder, as the enzyme is unable to catalyse the reaction.
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The enzyme reaction occurs in this way:
  Catalyst
   Enzyme Z
  X molecule → Y molecule
 Precursor   Product
All or part of molecule X fits into the active site of Enzyme Z, rather like a lock and 
key. Enzyme Z then converts X into the molecule Y. Sometime additional molecules 
are required as precursors and sometimes more than one product is produced.
Some biochemical testing measures the activity of an enzyme (e.g. phenylalanine 
hydroxylase) in a sample by either the appearance of a specific reaction product or 
the disappearance of a reaction precursor. Other biochemical testing involves testing 
for the presence and quantity of a specific metabolite (either a precursor or product). 
This testing is sometimes called spectrophotometry or colourimetric testing as the 
molecule being measured is detectable by a change in colour in a spectrophotometer 
machine compared to the colour in a control sample. The change in measured level 
of the molecule of interest is taken from the change in colour of the sample measured. 
From this measurement, the activity of the enzyme or quantity of a metabolite can be 
calculated. If the natural molecules involved in the reaction are not easily detectable 
by a spectrophotometer in the laboratory, then artificial ‘analogues’ are used (similar 
molecules that still fit like a key into the enzyme lock), which are detectable.
An immunoassay is the use of specific antibody/antigen recognition to perform a 
test. The biological sample can be tested either for the presence of the antigen (a 
specific protein) or antibodies to a specific protein.
An antibody is a molecule in the immune system that recognises a specific protein 
pattern. This recognition can also be described as a lock and key combination: only 
a particular key will fit in a specific lock. Specific (monoclonal) antibodies can be 
generated in the laboratory through cell culture. Antibodies for immunoassays may 
have fluorescent, coloured or radioactive molecules or enzymes artificially attached 
to one end, to enable detection. 
One of the reactants is fixed to a solid support (e.g. a plastic tray) and any sample 
that has not bound to the fixed reactant can be washed away. This allows for more 
accurate quantification of the molecule of interest, e.g. the amount of immunoreactive 
trypsinogen in the blood sample when screening for cystic fibrosis.
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.2  high performance liquid chromatography
High performance liquid chromatography (HPLC) is not used in newborn screening 
in New Zealand. 
HPLC techniques (and, in some programmes, isoelectric focusing) are used overseas 
to screen for blood disorders: the haemoglobinopathies, such as sickle-cell anaemia, 
and the thalassaemias. These disorders are predominantly found in populations of 
African, Mediterranean, Middle Eastern and Asia populations. They are thought to 
have become common in these populations because to have one copy of the relevant 
affected gene (allele) is protective for malaria. Having two copies of the relevant 
allele, however, causes severe symptoms from the effects on the morphology of red 
blood cells and generally results in premature death.
HPLC columns, specifically designed for haemoglobins, separate out the different 
types of haemoglobins according to how they travel through the HPLC column. The 
separation is measured according to the time each component (different type of 
haemoglobin) takes to come through the column and reach the detector. The column 
itself consists of a ‘solid phase’ that stays in the column and a liquid phase that travels 
through the column with the blood sample. Both the solid and liquid phases can be 
varied to ensure optimal separation of the sample being processed. 
There are a number of types of haemoglobin chain that combine to form a haemoglobin 
compound (Hb). The combination of four chains changes over time and a newborn 
profile is different from that of an adult. The predominant combination in newborns 
is called fetal haemoglobin or Hb F, with a small amount of the adult form, Hb A. 
The absence of Hb A and the presence of the sickle-cell form of haemoglobin (Hb S) 
is diagnostic for sickle-cell anaemia. 
.  tandem mass spectrometry
Tandem mass spectrometry (MSMS) is a method to separate and detect molecules 
on the basis of both size (mass) and electric charge. (For more detail on MSMS 
technology, see Chace et al., 2002.)87 These molecules can be electrically separated, 
using positively and negatively charged plates in the chambers, to alter their course 
through the chambers. This separation is used to remove molecules that are not 
going to be measured and to ensure that known fragments of interest are aimed at 
the detector.
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Figure 2: The results of a hypothetical screen and the balance between sensitivity and 
specificity.
The chemical compound of interest (test variable) can be detected in overlapping ranges 
in unaffected and affected individuals. The Y axis (not shown) is number of people. A, 
B and C are three potential cut off points for further investigation, each with differing 
specificities and sensitivities. 
Source: Wald and Leck, 200071
In newborn screening, the MSMS is used to measure individual amino acids and 
acylcarnitines in the heel prick blood sample. Amino acids, such as phenylalanine, 
are the building blocks of proteins. Carnitine is used to transport fatty acids (a 
component of fats and oils) around cells. A fatty acid attached to the transporter 
molecule carnitine is called an acylcarnitine. Acylcarnitines are named according to 
the length of fatty acid involved, e.g. C8 (octanoylcarnitine) is the fatty acid measured 
in particular in medium-chain acyl-CoA dehydrogenase (MCAD) deficiency and it 
has a backbone of eight carbons. They are sometimes more simply referred to as 
short, medium and long chain.
The tandem mass spectrometer is essentially two mass spectrometers lined up 
together and connected by a ‘collision cell’. The blood sample can be fed into the 
first chamber in a number of different ways to make it, for example, a gas-phase 
electrospray. MSMS equipment sometimes takes its name from this step in the 
chemical analysis. The sample is separated according to the constraints programmed 
into the computer. Molecules that get directed into the collision cell, by the first mass 
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spectrometer (MS), are broken up into smaller pieces and passed through the second 
MS chamber. The molecules are again separated according to the parameters of the 
test and those molecules of interest are directed towards the detector. The result is a 
graph as shown in Figure 4.
The two mass spectrometers can be loosely thought of as increasingly fine sieves: the 
coarse unwanted material is held back by the top sieve, allowing the more specific, 
finer material to proceed to the next step. The collision chamber breaks the material 
up further before it is separated again in the second sieve, allowing the ‘purified’ 
material of interest to pass through to the detector and directing unwanted material 
away from the detector.
Many types of acylcarnitines and amino acids can be measured within minutes, 
enabling the detection of many disorders.
Figure 4: MSMS readout for acylcarnitines, showing MCAD. The first result is from 
an individual affected by medium-chain acyl-coenzyme A dehydrogenase (MCAD) 
deficiency showing the accumulated acylcarnitine C8 molecule at around 345, the 
molecule diagnostic for the disorder. The second is from an unaffected control individual. 
Note the absence of a major peak for the C8 molecule. Intensity (vertical axis) indicates 
the amount of each molecule, by the height and width of each peak. IS indicates the 
internal standards used to guide peak identification





  what Does exPanDeD screening mean For  
 new ZealanD?
There seems little doubt now that expanded NBS using MSMS technology is a 
positive development for New Zealand. New Zealand would be following other 
countries in this respect, particularly Australia and the United States. More children 
with rare disorders are detected for little extra cost in testing, reducing mortality and 
morbidity.90 New Zealand is likely to follow international recommendations on how 
to screen and what to screen for, and there is much international experience to draw 
on, particularly from Australia.
Ostensibly, expanded metabolic screening is not very controversial anymore and 
few of the negative aspects of expanded screening are new. There is still sparse, 
but increasing, evidence that early detection can mitigate various effects of these 
disorders in young children.91 The main issues highlighted by the introduction of the 
MSMS would appear to be deciding which disorders are most effectively included in 
the screening panel and ensuring sufficient State resourcing (financial and medical) 
of the programme. 
Acylcarnitines (mass-to-charge ratio)
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.1  main scientific and clinical issues
Expanded screening has been added to a well-established newborn screening 
programme. This programme already has quality assurance, audit and evaluation 
aspects in place, with oversight by the newborn metabolic screening programme 
Advisory Group, the National Screening Unit and the relevant professional bodies. 
Whilst there have been additional requirements in terms of equipment and laboratory 
and clinical personnel, these were put in place well before expanded screening was 
offered. The equipment was tested using affected samples from the established New 
South Wales (Australia) programme and New Zealand has followed Australia’s lead 
with regard to the disorders on the screening panel.92
A factor that may or may not have some bearing on the future newborn screening 
panel is changing national demographics through immigration. In other words, ‘what 
does the population profile look like?’ This issue has prompted Britain to introduce 
universal screening for sickle-cell anaemia, moving from the previous screening that 
targeted those of African or Caribbean descent. With an increasing proportion of 
the New Zealand population being of Asian descent, it may be worth considering 
disorders such as the thalassaemias or glucose-6-phosphatase dehydrogenase 
deficiency for screening in the future.
Issues of cost/benefit and effectiveness can be guided by data from Australia and 
internationally. There is certainly data on effectiveness of early detection for MCAD 
and cystic fibrosis from Australia,93 but it would be useful to see New Zealand data to 
gauge the effectiveness of the programme in this respect. 
The main issues of expansion are not new, but in some instances are amplified. These 
concerns include, but are not limited to, unaffected carrier detection, which is already 
an issue for cystic fibrosis; false positives, resulting in stress for parents and increased 
use of clinical services for investigation; false negatives, meaning that the disorder 
may be excluded from future diagnosis; increased cost of following up anomalous 
results, because of increased testing; and incidental detection of untreatable disease.
.2  other new Zealand issues 
A number of other issues have peripheral interest from a scientific/clinical point 
of view.
The recent purchase of the New Zealand MSMS equipment was funded by a children’s 
charity, the Starship Foundation. Aside from the versatility of the equipment (used 
in both screening and diagnostics), it seems that the newborn metabolic screening 
programme is a core health service, worthy of State-funded support. This should 
include upgrades and support for new and improved technology, particularly as 
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this move aligned the New Zealand programme with the Australian screening 
programmes.
Education of consumers about newborn metabolic screening, from anecdotal 
reports, appears patchy at best. There is a requirement for ‘informed consent’ on the 
part of parents before the newborn’s heel blood sample may be taken. Up until now, 
there have been no major issues reported in New Zealand with respect to the lack of 
information provided, either before or at the time of sampling. As the programme 
continues to expand, as will invariably happen, the informed part of the consent 
process will become more crucial. The introduction of screening for untreatable 
disorders or even expansion to DNA screening requires that parents come to a 
considered conclusion about testing their newborn, in keeping with any other genetic 
testing processes. Awareness on the part of lead maternity carers, prenatal education 
courses, maternity/neonatal services and even parents must be raised. It may be easier 
to achieve this through gradual changes to education curricula and medical systems 
before any further expansion, rather than having a sudden change in processes later.
The use of the blood samples on stored Guthrie cards is about to undergo a consultation 
process. Currently Guthrie cards are stored indefinitely and most New Zealanders 
born since 1968 will have a card in storage. There appears to be official provision and 
support for using older samples for quality control and screen development, directly 
relating to the primary purpose of the screening programme, i.e. the detection of 
newborns with serious, early onset disorders. Allowing the stored blood samples to 
be accessed without consent for purposes unrelated to the screening programme is 
more problematic and has implications for the integrity of the programme.
Participation in the newborn metabolic screening programme is extremely high in 
New Zealand: over 99 per cent of newborns are tested.94 Yet, each year, a small but 
increasing number of parents are requesting their child’s Guthrie card back after 
screening. 95 Is there a perception of risk in segments of the community regarding 
the way in which their child’s DNA might be used in the future? Until now, the 
NMSP Advisory Group has carefully guarded the integrity of the programme by 
an extremely limited release of cards to the police (for forensic identification only), 
although the Courts can order access for paternity testing, for example. The Advisory 
Group has so far refused all requests to use the cards for scientific research unrelated 
to the programme.
Guthrie cards are a potentially valuable resource for many and varied lines of research 
by scientists and clinicians. Some such research may even answer important health 
questions for New Zealanders. Is there, however, a possibility of reduced screening 
coverage due to a perceived risk in the storage of cards evolving into a perceived risk 
in screening? Hopefully, the public consultation will go some way towards answering 
this and other questions. 
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In the meantime, any perception of secrecy or concealment with regard to use of the 
cards outside the primary purpose of the programme has the potential to severely 
damage the programme. Information and consent processes need to be consistent 
and of good quality to allay any possible fears. These processes are largely outside the 
control of the newborn screening programme. 
There is a possible corollary to be found in vaccination programmes, where a small 
number of vocal people are able to alter vaccination rates through wide dissemination 
of selective information or misinformation. If there is any threat to the success of 
the primary purpose of the programme in this manner, then secondary uses of the 
Guthrie cards must be continue to be stringently controlled or even stopped. 
The newborn metabolic screening programme is not a DNA bank or a biobank. It 
has not been designed in this way and does not have the processes and safeguards in 
place to be used in this manner. In addition, these samples are from predominantly 
healthy newborns. They are not taken because of apparent disease and they are not 
pathology samples or any other type of sample taken for specific medical purposes; 
so there is no emotional or other link between the purposes of the research and the 
family. Members of the public have not consented to their samples or their children’s 
samples being used in any way outside the screening programme. The programme 
must not be used as a tissue or DNA repository simply because it is the easiest way to 
answer a particular research question. There are almost always other paths that can 
be followed to answer the same research question.
7  molecular genetic screening – the inevitaBility?
For more detail on the implications of newborn DNA screening, please to refer to articles 
by Green and Pass,96 Kerruish and Robertson,97 the Human Genetics Commission98 
and Wilcken.99 For more detail on microarray whole genome screening, please refer to 
‘Genetic testing and microarray technologies’ by Genevieve Matthews in this Report. 
Whilst molecular genetic (DNA) newborn screening ostensibly has the same aims as 
metabolic screening, i.e. detection of potential medical problems, it has far greater 
potential to detect medical issues far into the future. DNA screening can detect 
conditions that may not arise until middle age or even later, whereas metabolic 
screening is currently limited to the early years of life (or around the time when the 
blood sample is taken).
DNA screening has the potential to predict a wider range and greater number of 
disorders, an advantage from a purely public health perspective. There are, however, 
many issues left to deal with from scientific, clinical, ethical, legal and policy points 
of view. This section will focus on the scientific and clinical limitations and future 
promise of DNA screening.
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7.1  what is different?
Newborn DNA screening would involve analysing the DNA contained in the blood 
spots, rather than the metabolic molecules. Testing could even move from blood to 
some other bodily sample, such as a cheek cell swab. By examining the DNA for changes 
(mutations) known to cause specific disorders, it would be hoped that, if the screening 
were performed early enough, more disorders would be predicted before any symptoms 
or damage were detectable. Early detection enables early treatment, if available, or 
modification of environment for those disorders that respond to such changes.
Short of creating an entirely new population-screening regime, with different 
screening times, the time of newborn screening remains convenient for undertaking 
additional screening. It is also a time where many, but not all, disorders have not yet 
begun to develop. Conversely, there is much controversy around the idea of predictive 
genetic screening for later-onset disorders, even for people with a known risk. This 
may provide the impetus to drive a more selective screening programme with various 
screening points over time; perhaps even integrating existing (non-DNA) screening 
programmes such as breast cancer screening.
Newborn genetic screening using DNA analysis of newborn blood spots is likely to be 
considered more seriously in the future as genetic testing technologies improve and 
become cheaper. Concomitant with improvements in technology are improvements 
in knowledge regarding the basis of genetic disorders. Advances include identification 
of disease-causing mutations and interpretation of genetic data to give a more 
accurate estimation of risk.
High throughput, massively parallel (microarray) technology in particular is a likely 
candidate technology for screening in the future. Microarray systems can screen from 
hundreds to hundreds of thousands of specific genetic variants in a short time, but 
are only just starting to move from research trials into clinical use. Whole genome 
sequencing is also a possibility in the longer term. Microarray technologies are explained 
in more detail in the prenatal whole genome screening sections of this Report.100
There are, however, some issues with the use of DNA screening that do not exist 
with the indirect metabolic screening. So, what are the differences between newborn 
genetic (DNA) screening and newborn metabolic screening?
7.1.1  Metabolic versus genetic screening
Concerns typically raised around DNA screening relate to overlapping aspects of 
various screening criteria: test validity; availability of treatment; the predicted severity 
and the natural history of the disorder; and, specifically, the risk of developing a 
disorder (penetrance and expressivity). Penetrance is the percentage of people who 
are at risk and who actually go on to exhibit symptoms. Expressivity is the degree to 
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which the symptoms manifest, i.e. severity. Issues of cost will likely resolve themselves 
as the technology improves and becomes more common.
The crucial difference between the two types of screening is that metabolic testing 
is symptomatic, whereas DNA screening is predictive. Metabolic screening detects 
abnormal levels of molecules in the body, which may be as a result of genetic disease. 
If there is no disease present then these metabolites will usually be within the 
normal concentration range. DNA screening, with our current level of knowledge 
and technology, detects some mutations that probably cause disease. In both types of 
screening, further investigation of an at-risk result would be required. 
The measurement of abnormal metabolite levels is symptomatic testing; in other 
words, there are possible signs of disease development that can be followed up. Even 
when the obvious physical symptoms have not developed, the abnormal metabolite 
levels themselves are a symptom or phenotype (physical result of a DNA genotype) 
and evidence of a disorder that will likely develop further. 
DNA screening is predictive; but the existence of a specific genotype (DNA sequence) 
is not deterministic, merely indicative of what may occur in the future. A number 
of factors must be taken into account before a risk prediction of a future disorder 
can be made from DNA sequence alone. With a few disorders, this risk assessment is 
straightforward because a particular change in a single gene invariably results in the 
symptoms of the disorder, e.g. Huntington disease. 
For other disorders, using current knowledge, it is impossible to predict accurately 
that a person will develop symptoms and a higher follow-up rate may be expected. 
For example, in one study of the most serious haemochromatosis mutation, two 
copies caused one person of a group 152 homozygotes to go on to develop the 
blood disorder.101 This demonstrates a low penetrance102 and, whilst the treatment is 
relatively simple (regular blood donation), it may be unnecessary if a person never 
develops any symptoms. Children with DNA mutations known to cause particular 
conditions occasionally receive negative test results under the metabolic screening 
programme. Guthrie cards in New Zealand are stored indefinitely, partly to follow 
up on these rare occurrences, potentially enabling staff to refine the metabolic test 
further. The lack of development of symptoms (penetrance) or reduced severity of 
the disorder (expressivity)103 may be because of a weak genotype/phenotype link 
and/or many (known and unknown) modifiers. Until more is known about such 
disorders, they are unlikely to be included on a screening panel, even if there is a 
simple treatment as with haemochromatosis.104
DNA screening, using a limited panel of serious or common mutations, is likely to 
miss some children with rare or uncharacterised mutations leading, in theory, to a 
lower detection rate. This issue is discussed further in section 7.4.1 on cystic fibrosis. 
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If DNA screening were introduced today as a replacement for metabolic screening, a 
DNA genotype would be a signal for close monitoring of the child – in all probability 
looking for changes in metabolite levels. Some children would not be detected at all, 
as not all causative mutations have been identified.105 These children could develop 
symptoms without any early recognition or treatment, if in fact treatment exists.
DNA screening, however, may be able to detect those with later-onset variants of 
those disorders in newborn screening panels.
Sometimes children, such as those with some neonatal-onset classical organic 
acidurias, have a medical crisis before their disorder is identified through metabolic 
screening.106 DNA screening of, particularly metabolic, disorders could exacerbate 
the number of these occurrences due to the time (currently) taken to complete the 
DNA screening and follow-up analysis. This risk of an early crisis is lower for some of 
the disorders currently being considered for DNA screening (e.g. fragile X syndrome) 
as they are, for the most part, slightly later onset. Children may not exhibit symptoms 
for months or a few years after birth. Technological advances may eventually minimise 
this risk, through some combination of improvement in the speed of screening and 
shifting of the time of screening. 
Other children who could be disadvantaged by DNA screening alone are those 
inadvertently detected through the current metabolic screening programme. These 
are children, with disorders that are not specifically tested for, who have an abnormal 
result for one or more metabolites using metabolic screening.107 Currently, in New 
Zealand, these children will be followed up by a metabolic physician; but, unless the 
problem is actually of genetic origin and there is detailed screening of the newborn 
genome, it is possible that DNA screening will not detect at least some of these 
children. This non-specific detection ‘feature’ of metabolic screening is not regarded 
by everyone as an advantage, however, and this information can be specifically 
excluded by focusing solely on the metabolic molecules of interest. Alternatively, more 
children with disorders may be identified using new DNA screening technologies, 
depending on how the technology is used.
The heel prick to obtain blood for metabolic testing cannot be performed at birth: 
a short wait of approximately twenty-four hours is required to allow the maternal 
influences on the child’s metabolism to subside. DNA screening on the other hand 
may be performed at birth, and potentially may be performed before birth. An 
amniocentesis sample, for example, is tested for major chromosomal abnormalities 
including whole chromosome changes (aneuploidy) and large deletions and 
duplications (segmental aneuploidy). Amniocentesis is currently used as a de facto 
aneuploidy screen in New Zealand, due to the lack of any other comprehensive, 
reliable screening programme. There is no physical reason why this sample could not 
be used for other genetic analyses. On the other hand, there is a risk of miscarriage 
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from the amniocentesis procedure, so screening of all fetuses is not feasible unless 
non-invasive sampling techniques can be developed.
DNA screening, as opposed to metabolic screening, is not affected by such factors 
as an early blood transfusion and prematurity.108 These aspects can and do affect 
metabolic screening results, sometimes masking an existing disorder. An obstructed 
bowel (meconium ileus), for example, can mask the detection of cystic fibrosis in a 
newborn, although this symptom is in itself a signal for further investigation.
In addition, all known disease-causing mutations can be added to a microarray 
screen for a specific disorder. This ability could certainly benefit non-Northern 
European populations in the case of cystic fibrosis, where the delta F508 mutation 
is a far less common cause of the disorder. Whilst it is possible that some children 
would miss being diagnosed, even screening with all ~1500 known mutations, the 
risk is particularly small compared to using only twenty-three mutations, as with the 
United States cystic fibrosis prenatal screening programme. There is also certainly an 
opportunity for application of microarrays in diagnostics.
There are currently some serious limitations to widespread DNA screening:
• Not all disorders are of primarily genetic cause. An excellent example of this is 
congenital hypothyroidism (see section 3.2). Whilst a small proportion of cases 
have a heritable genetic cause, most do not. Congenital hypothyroidism would 
necessarily continue to be screened for metabolically. DNA screening would 
also not replace newborn screening for hip or heart defects and hearing deficits, 
although it could be used in conjunction with traditional screening for the last 
two issues.
• Not all DNA mutations that cause disease are known; not all modifiers of 
mutations are known either. This may lead to great difficulty interpreting any 
information derived from DNA screening. A person’s genetic background is 
not immediately relevant for primary metabolic screening and it is only when 
the characterisation part of the diagnostic process starts that genetics become 
pertinent.
• The presence of specific DNA mutations does not automatically lead to a disease 
state. In comparison, metabolic testing only attempts to detect the developing 
disease state. DNA screening will inevitably lead to the detection of children 
with very mild or no symptoms, who require no treatment. 
• Short of sequencing the whole genome, not all disease-causing mutations are 
able to be detected (technological limitations) and not all should necessarily be 
automatically detected (for ethical reasons), for example, because they have high 
environmental influences (lessening the predictive value) or are very late onset. 
There is much debate around the latter issue.
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• There is the potential to widen DNA screening to sequences in the genome 
that have no direct bearing on physical health status, such as behavioural 
or psychological traits. Traits such as these typically have a very high 
environmental component. The effects and long-term consequences of using 
DNA screening in this manner are unknown but are generally predicted to be 
unhelpful to the individual.
• There is a lot of evidence to suggest that the medical system is not currently 
equipped to deal with genetic information such as this,109 particularly at 
the primary health-care level, but also in more specialised areas. Substantial 
investment in training and additional recruitment of trained personnel (such as 
laboratory staff, genetic counsellors/associates and clinical geneticists) would be 
required even to start pilot programmes, let alone widespread screening.
Many of the current scientific limitations of DNA screening will be mitigated, if not 
solved, in the future. Improvements in technology are widely predicted and, with 
increasing use of genetic testing or screening technologies, genetic information will 
be more easily interpreted through the use of information in extensive databases. 
The question of benefit to the child from newborn screening becomes much more 
equivocal in these situations, even ignoring the presence or absence of a treatment 
and more complex issues such as privacy and autonomy. Significant benefit and cost 
effectiveness will need to be comprehensively demonstrated before DNA screening is 
introduced across-the-board in any programme.
7.1.2  Genotype/phenotype relationships
The general perception of autosomal recessive disorders is that, if an individual has two 
non- or sub-functional copies of a gene, then they will exhibit a standard single gene 
trait or disease. Unfortunately (or fortunately), genetics is not as straightforward as this, 
and many factors can modify whether the expected phenotype is exhibited or not.
There are many reasons why a disease genotype, revealed by DNA testing, may not 
manifest as a disorder phenotype. Influences from other parts of the genome and the 
environment are responsible for this variation; but, for many disorders, the specific 
reasons behind the variation are unknown.
7.1.2.1  Haemochromatosis
Haemochromatosis is an iron-overload disorder, due to a failure in normal iron 
metabolism. Excess iron in the body is deposited in various organs over time, 
potentially (but not necessarily) causing damage including cirrhosis and cancer 
(liver), diabetes (pancreas) and heart failure. It is easily treated by regular withdrawal 
of blood, for example, by donating to blood banks. There are four main types of 
inherited haemochromatosis, caused by mutations in different genes.110
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Classical haemochromatosis (the focus in this section) is an adult-onset, recessive 
disorder. There is one very common disease allele of the HFE gene in Northern 
European populations, the C282Y allele. Two copies of this allele are also associated 
with the highest risk of the disorder.111 Because of the ease of treatment, it has been 
suggested as a good candidate for population screening.
Haemochromatosis is a partially penetrant disorder, however, and not all homozygotes 
for the above mutation will go on to develop iron overload, let alone disease of the 
various organs. Whilst quality data is lacking, it is estimated in one review that 38 per 
cent to 50 per cent of homozygotes with the C282Y allele will develop iron overload 
and 10 per cent to 33 per cent will develop disease in the long term.112 In other 
words, over 50 per cent of people at risk will never develop symptoms. Another study 
estimates the risk of serious disease to be substantially lower at ~1 per cent; although 
there was later some scientific criticism of the methods used.113 The risk of disease is 
lower for people with less penetrant haemochromatosis-causing HFE alleles.
The basis upon which some people develop disease and others are asymptomatic 
is unknown. There is also no consensus regarding whether or how to treat 
asymptomatic homozygotes, although closer monitoring of health will allow 
intervention where serious disease might have otherwise been missed. 114 Besides the 
possible psychological effects introduced by a positive genetic test for susceptibility 
(shown to be unfounded in one Australian study),115 there may be implications for 
health insurance eligibility in some countries. For these reasons, population screening 
has never been implemented, despite the ease of treatment. It is a likely candidate, 
however, if widespread DNA screening should ever be introduced.
7.1.2.2  Phenylketonuria (PKU)
PKU was one of the first disorders to be screened for in newborns. It has been observed 
that, even with this classically Mendelian (single-gene) disorder, the severity of the 
symptoms may vary between siblings who have the same genetic origins. 
Clearly, PKU shows variability in severity because it can be caused by a number 
of mutations in different parts of the phenylalanine hydroxylase (PAH) gene. This 
variation is due to the differing effects of the individual mutations on the active site 
of the enzyme produced from the gene, as well as changes to regulation, protein 
folding, protein aggregation and/or protein stability.116 It has been demonstrated, 
however, that these properties can be modified in the laboratory by changes to 
proteins that help other proteins fold correctly (chaperonins), as well as by changes in 
environmental temperature. It is entirely possible that these same changes could help 
modulate the PAH enzyme in people too, explaining at least some of the variation 
seen in people with the same causative mutations.117
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A more expansive explanation is postulated by Scriver.118 He suggests that the 
phenotype (physical effects) seen in PKU can be further divided into the enzyme 
phenotype, the metabolic phenotype and the cognitive phenotype. The enzyme 
phenotype, aside from variability from the causal mutation(s), is modified by 
variability in protein folding and degradation systems in the body; the metabolic 
phenotype is where there may be variation in phenylalanine transport and processing; 
and the cognitive phenotype is subject to variation in phenylalanine transport into 
the brain. These three different phenotypes probably have some genetic basis, not just 
in the PAH gene. All of these phenotypes are in turn modified by the environment, 
diet being the major influence in the case of PKU. 
7.1.3  Whole genome screening versus selective screening
There is potential to screen for many more disorders simultaneously with DNA 
screening than with current technologies. There is the capability to target early onset, 
serious disorders, as in current screening programmes, or to expand the screening 
panel to all known single-gene disorders or even more widely in the future. Some 
of these conditions may not be ‘serious’ or may not manifest themselves in the early 
childhood period, two criteria that are widespread in many newborn screening 
programmes. Commentators in the literature are only now starting to explore some 
of the implications of extending ‘newborn’ screening in this way. Although many of 
these issues are not new for individual genetic testing in those with a known risk, they 
are greatly magnified when looked at from the viewpoint of a low-risk population.
There are three basic alternatives for the use of DNA screening of populations: keep 
to same criteria currently used in newborn screening and limit screening to a small 
number of high-risk newborn disorders; screen for many disorders at newborn stage; 
or expand the screening, but adopt different time points according to when a disorder 
is most likely to develop. There is also a choice to be made about whether to limit 
screening to serious, single-gene disorders or all single-gene disorders, or whether to 
expand into more complex genetic disorders such as heart disease and Alzheimer’s 
disease. This type of widespread screening has many more ethical, psychological and 
social implications than does targeted newborn screening, as many more factors are 
involved in causation of disorders and accurately predicting risk is far less precise.
The use of whole genome screening or even whole genome sequencing can be likened 
to a genetic health scan. On the one hand, there may be value in knowing that there 
is a future risk. On the other hand, a genetic health scan has similar pitfalls to the 
use of a whole body screen, such as a computerised tomography (CT) scan, as a 
general health measure (rather than for diagnostics) including false results.119 Merely 
by having a scan, there may be risks to physical and psychological health and well-
being through possibly unnecessary investigation as a follow-up to any unfavourable 
results, whether high or low risk. 
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The pros and cons of each strategy will have to be seriously considered and balanced 
against available health resources before comprehensive genetic screening is offered 
to the general population.
7.2  Practical considerations of Dna screening
A number of practical considerations may affect whether and how whole or targeted 
genome screening might be used.
Microarray screening of the genome is similar to MSMS screening, in that it is easy 
and relatively cheap to add new disorders to a screening microarray. Additional 
screening is even easier for whole genome sequencing as the data is already available: 
the data simply needs to be identified and analysed.
Potentially the major factor regarding if and how genetic screening is used is the issue 
of intellectual property ownership and licensing of patented genetic information or 
tests. This issue is already affecting how genetic tests are used in general, including 
which tests are available on diagnostic microarrays.120 Tests that are protected by 
intellectual property (IP) rights may be freely available and are sometimes patented 
solely to ensure this availability. Alternatively, the information that is the basis of the 
IP may be restricted either by pricing or even by limited availability to particular 
licensees. Limiting access in either manner tends to restrict the availability of tests on 
comprehensive microarray screens for some genetic mutations or even whole genes.
‘Informed’ consent will still need to be obtained to perform this type of genetic 
screening in New Zealand. Whilst it is, for the most part, impractical to obtain 
consent for each test on a microarray, the tests could be grouped in some way and 
separate consent obtained for each group. Tests could be grouped, for example, 
by age of onset, severity or complexity (e.g. heart disease, with multiple genes and 
environmental influences, versus hereditary breast cancer, with one or few genes 
and low environment effects). Separate consent for DNA screening as part of a 
multiplatform screen, for example of newborns, is also desirable.
If the usual genetic testing standards are to be adhered to, then there are extra 
counselling requirements to be met for genetic screening. Counselling should be 
performed by persons trained in genetic counselling, further increasing the demand 
for genetic clinicians and counsellors. This increase in demand would require training 
of additional staff, or education of alternative personnel such as general practitioners 
and midwives. General practitioners’ knowledge of genetic services has already been 
shown to be in need of improvement, so counselling and communication of results 
would require a substantial investment.121
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Partial or whole genome screening and sequencing generates large quantities of data. 
If this data is to be kept for some future use, then a number of factors need to be 
considered in this storage. There must be enough capacity physically to store and 
back up the raw and/or processed data. There must also be systems for accessing and 
analysing this information in a meaningful way. Additionally, the security of the data 
must be protected at least as well as any other personal information. Some would 
argue that protection systems should be better than for other personal information. 
Alternatively, if costs are reduced enough, the data could be regenerated each time 
it is required. The requirement for storage would be reduced; although other factors 
such as analytical capacity and security for the duration of the existence of the data 
would still be required. Security would at some stage have to be assumed by those 
holding that individual’s medical records.
7.  children’s issues
The debate around testing children for genetic disorders is vigorous. This issue is 
comprehensively covered in the section of this Report entitled ‘Genetic testing of 
children who cannot give a valid consent’ by Deborah Lawson. Diagnostic DNA 
testing is generally considered acceptable, as there is (in theory) already an existing 
disorder. Where there is demonstrable, direct benefit to a child, in terms of treatment 
or cure, then predictive DNA testing for early onset disorders is also considered 
acceptable – although when this testing should be performed is more contentious. 
When and whether to test for later-onset and untreatable disorders is where the 
debate polarises, with much speculation and little evidence on both sides. There 
appears to be a continuum of acceptability, with screening for earlier-onset disorders 
typically considered more acceptable than screening for adult-onset disorders. Early 
testing for later-onset breast cancer (BRCA 1 and 2 mutations), for example, is more 
controversial than screening for earlier-onset (often in the teens) colorectal cancer 
(familial adenomatous polyposis). 
Some commentators consider that screening should not be refused out of hand and 
that clinicians and counsellors should carefully consider requests for early genetic 
testing.122 Factors to be considered include ease of psychological adjustment in young 
children, ability to access new treatments or research trials and parental knowledge of 
the capacity to understand and temperament of the child. Others consider that privacy 
issues (including the ability to stop parents telling anyone, compulsory disclosure for 
insurance and employment problems), potential pressure to participate in research 
and the later autonomy of child override any desire on the part of the parents for 
early genetic testing.
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There appears to be a consensus in the literature that any testing or screening should 
be ‘in the best interests’ of the child. There is no consensus on what this phrase 
actually means. Best interests can be narrowly construed, focusing on available 
medical treatment; or it can be interpreted more widely, looking, for example, at the 
child in the context of the family unit, psychological adjustment, opportunities to 
enrol in treatment research programmes and educational opportunities. 
As mentioned, this is a polarising debate, with little actual evidence on either side. 
Any attempt to introduce widespread DNA screening will need to be considered on 
the basis of well-designed, small pilot programmes and carefully analysed data.
7.  genetic programmes in use
A small number of DNA screening programmes have been employed internationally, 
such as those for type 1 diabetes (IDDM).123 They are, for the most part, small 
research or pilot trials but one, cystic fibrosis screening, is being routinely offered 
to couples planning or starting a family in the United States. Positive and negative 
aspects of these programmes have been discussed and can inform the debate on 
newborn molecular genetic screening.
7.4.1  Cystic fibrosis prenatal screening programme
Typical cystic fibrosis (CF) is a recessive disorder, resulting from mutations in the 
‘cystic fibrosis transmembrane conductance regulator’ (CFTR) gene. Richards and 
Grody,124 Watson et al.,125 Farrell and Fost126 and Uphoff and Highsmith127 offer more 
detail on the United States cystic fibrosis screening programme. Two (asymptomatic) 
carriers of CF mutations have a one in four chance of having an affected child. There 
are currently 1523 documented mutations in the CFTR gene worldwide,128 although 
most of these are extremely rare or unique. This gene codes for a chloride ion 
channel in epithelial cells (cells that are in contact with the outside environment). If 
the protein is non-functional or absent, due to degradation of the abnormal protein, 
then the lack of chloride ion transportation affects many organs.
Cystic fibrosis, in its most serious form, is a condition that affects the lungs, pancreas, 
digestive system and male fertility, amongst other bodily systems. Although severe CF 
is now survivable past childhood, using physiotherapy and pharmaceutical treatment, 
it can still substantially shorten the lifespan. The average lifespan for someone with 
serious CF is now just over thirty years.129
The most common and severe mutation is a three-nucleotide deletion that removes 
a phenylalanine amino acid from the protein (deltaF508), resulting in a protein that 
misfolds and degrades in the endoplasmic reticulum. More than 80 per cent of cystic 
fibrosis cases are due to this single amino acid deletion in CFTR in those of Northern 
European descent.130 This incidence is lower in other ethnicities.
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Cystic fibrosis is a variable disorder although some mutations are classically associated 
with characteristic symptoms. The deltaF508 phenotype is typically coupled with 
severe pulmonary symptoms and pancreatic insufficiency. Puzzlingly, however, some 
homozygotes for this mutation do not have any lung disease.131 Pancreatic insufficiency 
does seem to be more closely correlated with particular mutations and the severity 
and age of onset of lung symptoms may be affected by environmental factors such 
as exposure to tobacco smoke, pollution and pathogens.132 Even amongst affected 
siblings with the same genotype (deltaF508/D614G), however, there is variation in 
the severity of pulmonary and pancreatic symptoms.133
Some sequence variants may be modified by another mutation. One example of this 
influence is the 5T polymorphism effect on the R117H polymorphism. Whilst the 
5T is a common variant in the population, its presence transforms the often-mild 
R117H variant into one with more severe effect.
In 2001, the American College of Medical Genetics (ACMG) and the American 
College of Obstetricians and Gynaecologists (ACOG) recommended134 that DNA 
testing for common, serious cystic fibrosis-causing mutations be offered to all 
prospective parents (planning a family or currently pregnant), as a standard of care. 
This followed a 1997 NIH report135 to the same effect. If both parents are found to 
carry a CF-causing mutation, they can choose to test the fetus for CF status or, if 
not yet pregnant, to use preimplantation genetic diagnosis to screen embryos before 
transfer and implantation – or even to not have biological children.
The original report recommended a core panel of twenty-five mutations for general 
population screening, each with a minimum cystic fibrosis population frequency of 
0.1 per cent. These mutations were selected for their ability to cause severe disease, as 
well as their frequency in the United States population. The panel was later reduced 
to twenty-three mutations, as early testing revealed the actual frequencies of cystic 
fibrosis-causing mutations in a population of such mixed ethnicities. There are also 
four modifying mutations screened for as reflex136 tests, depending on the primary 
screening results, e.g. the presence of the R117H allele.137 The screening programme 
should only test for the presence of these four modifying alleles (including the 5T allele) 
after a positive screen for the allele that they modify – the R117H variant in the case of 
the 5T allele. When screening parents for carrier status, the 5T and R117H variations 
must be on the same chromosome to pose a risk of cystic fibrosis to a future child. 
Whilst this panel will detect many or even most couples at risk, a low-risk test result 
is not a guarantee of a child free from CF, as there are numerous different, rare alleles 
not screened for. As the panel is based on allele frequency in the whole United States 
population, minority populations with different CF allele frequencies are likely to 
be disadvantaged. Any increase to the screening panel, for example through use of 
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microarray screening, will reduce the chance of being misclassified as low risk. On 
the other hand, interpretation of risk or expected severity of CF from the extra data 
may cause additional problems. In some areas or even practices in the United States 
screening is offered routinely; in others it is not offered at all, depending on factors 
present in the medical community.
There does seem to be some confusion generated by the programme, both in those 
being tested and those communicating the test results. There is growing evidence 
that many people undergoing testing do not truly understand and/or remember 
what they are being told. In some older studies, ‘confusion amongst carriers has 
exceeded 50 per cent’.138 Although there is a duty to communicate information at 
a level that can be understood by those to be screened, some of this information 
is sufficiently complicated that some practitioners themselves are not equipped to 
grasp the details.139 Whilst informed consent is important, because there are possible 
implications for insurance or non-paternity, most confusion appears to arise from 
interpreting and communicating results to those screened.
In one unfortunate incident, approximately thirty women underwent an unnecessary 
amniocentesis after mistakenly being screened for the 5T polymorphism as a primary 
test, rather than a follow-up (reflex) screen.140 The presence of the 5T allele in the 
absence of the R117H allele is not a risk factor for CF.141 Amniocentesis carries a 
~0.5 per cent risk of miscarriage. This incident is thought to have arisen through 
guidelines not being followed. ‘There have also been “unconfirmed anecdotal reports” 
of mothers aborting fetuses based on bad information, said Michael Watson …’142 
Watson repeated this assertion about the cystic fibrosis screening programme at a 
recent symposium on prenatal testing.143 
Despite these reported problems with the screening programme, ‘[i]t is increasingly 
clear that CF carrier screening can be carried out in some primary care settings 
with a high degree of patient satisfaction, high levels of patient understanding, and 
high levels of interest among pregnant couples …’144 It seems that this is a screening 
programme that laboratories and medical professionals will grow into with time.
7.4.2  Complex genetic disorders
Complex genetic disorders, also known as quantitative or multifactorial disorders, 
are those with multiple and often variable contributing factors. These causes can be 
different genetic factors, as well as environmental influences. The genetic factors may 
also predispose the individual to react to a particular environment in a certain way. In 
the case of heart disease, for example, those individuals with a genetic predisposition 
to atherosclerosis (narrowing of the arteries) are more likely to develop severe fatty 
plaques in their arteries when they have a poor-quality diet – high in saturated fat 
– than those without a genetic predisposition.
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As there are multiple factors involved in complex genetic disorders, often many 
unknown, it is very difficult to make predictions of future health based on just 
one factor, i.e. a single genetic test. As we have seen, even so-called ‘simple’ genetic 
disorders can be difficult to predict from this information. 
Type 1 diabetes or insulin-dependent diabetes mellitus (IDDM) is one such complex 
disorder that develops in young children. Genetic susceptibility involves a major 
single-gene contribution and multiple smaller contributions from many other genes. 
In addition, there are, as yet unknown, environmental factors that influence the 
development of the disorder. The challenges of using genetic testing for prediction of 
type 1 diabetes are discussed more thoroughly in the section of this Report entitled 
‘New possibilities for newborn genetic screening: Screening for genetic susceptibility 
to common disease’ by Nikki Kerruish.
7. Future of newborn Dna screening 
In the near future, DNA screening will most likely be used as an adjunct to, not as a 
replacement for, metabolic testing for specific disorders. In the longer term, it seems 
likely that there will be some form of genome screening as the technology and the 
knowledge to interpret this type of information improves.
It would seem to be a mistake to replace a successful metabolic screening programme 
simply because there is a newer technology available. Whilst it is likely that the 
metabolic screening technology will continue to evolve, it is unlikely that it will be 
replaced entirely by DNA genetic screening in the immediate future. The body of 
knowledge with regard to causes and particularly modifiers of genetic disorders 
is growing; but it is currently modest and is likely to remain so for some time, 
particularly for very rare diseases (such as those typically in the screening panel) and 
disorders with multiple genetic and/or environmental factors.
It is far more likely that, as the costs of DNA testing come down, new disorders 
will be added to the screening panel, whose tests are based on DNA analysis. There 
are a number of more common (non-metabolic) genetic disorders that develop in 
childhood and which were considered by the ACMG screening report.145 Whilst they 
did not score highly enough to be recommended for inclusion in the screening panel, 
this time at least, it is probable that these disorders will be reconsidered for inclusion 
in the future (with others). With the rapid evolution of appropriately predictive and 
cost-effective tests, they will likely be added to the screening panel before long.
One example of such a candidate genetic disorder is fragile X syndrome, which is 
almost solely caused by a trinucleotide repeat expansion in the FMR1 gene. Testing 
for one known and well-characterised mutation is more straightforward than testing 
for the ~1500 mutations characterised (so far) for CF. Whilst there is no known 
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treatment (in common with many of these non-metabolic disorders), early detection 
would enable reproductive choices for parents, minimise the ‘diagnostic odyssey’ and 
enable planning for future education, e.g. specialised learning programmes.
Aside from practical issues in the use of genetic screening, social issues exist, 
with DNA screening being perceived as riskier than metabolic screening. There 
are potential issues of public trust and confidence in the areas of science, privacy, 
discrimination and general understanding of genetics etc.146 In addition, there are 
concerns associated with the accurate communication and evident misinterpretation 
of results, both by consumers and, in some instances, providers. Many of the 
problems postulated around public acceptance and comprehension are ill defined 
and may be overestimated,147 as there is little evidence either way. Personal and public 
understanding of risk relating to genetic information is likely to be linked to all these 
factors, as well as to personal and group experiences.148
Many predict that microarray technologies or even whole genome sequencing will 
eventually (and perhaps sooner rather than later) become sufficiently inexpensive 
and rapid as to be used as a profiling technique. As information about the causes of 
genetic disorders becomes increasingly detailed, it is likely that this profiling will be 
performed shortly after birth. This idea has recently been discussed in the United 
Kingdom and dismissed, but only for the meantime. 149
There are two possible uses of this detailed information. One involves profiling the 
individual for all possible genetic risks and possibly attempting to reduce or mitigate 
the risks from birth, either medically (pharmacologically or surgically) or through 
lifestyle modifications. One commentator observes of lifestyle changes:
… the pious hope that knowledge might lead to beneficial lifestyle alterations 
seems likely to remain just that – a pious hope. We have not yet learned how to 
ensure that people take advice about harmful lifestyles.150
The other usage of genetic profiling information involves interrogating the genetic data 
only as needed. For example, a newborn’s sequence could be examined only for risk 
of early-onset, serious conditions. It could also be examined for serious, later-onset, 
single-gene disorders (such as some cancers) in the interests of monitoring, prophylaxis 
and/or family planning. Having said that, for many dominant familial cancers, there 
is generally already a family awareness of risk and this usage could merely supplant 
testing already performed at various developmental stages. Genetic information could 
be examined at later, defined, times for risk of progressive later-onset disorders. The 
timing would have to be carefully considered, however, as tissue damage may start well 
before symptoms manifest. The psychological and social aspects of this information 
must also be considered, preferably on the basis of credible evidence generated by pilot 
projects rather than speculation about possible harms and benefits.
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Stored genetic information could be used diagnostically, if the individual were showing 
possible symptoms of a specific disorder, presumably not already screened for. The 
information could also be used to optimise treatment, by examining which drug or 
drug dosage might be most effective, based on the genetic data (pharmacogenetics).
The reasons given for dismissing newborn DNA profiling in the United Kingdom were 
principally to do with the state and cost of current technology.151 Ethical and social 
concerns were raised but the report recommended that the issue be re-examined 
in five years’ time. This finding does not speak to irreconcilable flaws in the idea, 
although the other concerns will assume increasing importance as the technological 
and cost concerns are resolved.152
  conclusions
1. The Wilson-Jungner criteria that have been used as a foundation for newborn 
screening are not necessarily entirely relevant to newborns and their families, 
having originally been formulated in 1968 for chronic adult disorders. Changes 
in technology and society and differences peculiar to newborn screening, as well 
as scientific and clinical evidence, must be taken into account in reformulating 
criteria specifically for newborn screening.
2. Much of the controversy (although not all) around newborn screening in the 
United States is unique to and driven by that particular political environment. 
The absence of federal funding means that the State, insurance companies and 
consumers must fund the programmes and that each programme is determined 
State by State. Many programmes also have an element of compulsion, as 
opposed to New Zealand where parents must actively consent. In addition, 
the health system that supports these potentially expensive treatments is 
driven by private health insurance for those who can afford it (and are not 
judged a liability), limited State-funded care for the very disadvantaged and 
little for those outside these two groups. An insurance-driven health system is 
central to many of the heightened concerns around data privacy, employment 
discrimination and future access to affordable health insurance.
3. The current New Zealand newborn metabolic screening programme appears 
by any available measure153 to be a competent and successfully run programme, 
given the good detection and participation rates. The staff is committed to the 
success of newborn screening, is progressive in attitude towards the benefits of 
screening and fosters good links with other (international) programmes. The 
staff and Advisory Board have thus far been careful to avoid negative publicity 
and have carefully managed access to the Guthrie cards in the interests of public 
confidence in the programme. New Zealand is well placed to have a flexible 
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and responsive screening programme, given the small population, the single 
medical contact for each child (the lead maternity carer), a nationally consistent 
screening panel, centralised testing and State funding.
4. New Zealand is following international trends in newborn screening but not in 
too hurried a fashion. Even before expansion, New Zealand was screening for 
a respectable number of serious disorders (more than, for example, the United 
Kingdom). New Zealand has been able to use the implementation lag to absorb 
knowledge and experience of these new technologies from overseas countries 
and to put in place adequate support services, e.g. to employ a clinical metabolic 
specialist, before launching MSMS screening.
5. There is little public awareness of the successful New Zealand newborn 
programme, beyond recognition that ‘the heel prick test’ is a routine procedure 
for newborns. The NMSP is shortly to consult on various aspects of the 
programme and the storage and use of the Guthrie cards in particular. This 
consultation is a positive move given the apparent (anecdotal) growing distrust 
and misinformation surrounding the use of DNA samples and, therefore, 
Guthrie cards. The small but growing number of parents requesting the return 
of the cards154 evidences some distrust and sensitivity around potential uses of 
the DNA samples. This may have implications in the future for the screening 
programme when DNA screening is introduced (in whatever form).
 It could be productive to make more education and information available 
regarding the programme, particularly in antenatal classes and on the internet, 
but also amongst the general population, for example popular science reporting 
in the media155 or in the context of a ‘future screening’ public consultation. 
Education of parents-to-be in the third trimester of pregnancy is not a new idea 
but has been slow to be implemented by maternity service providers.
 Within copyright bounds, it would also be useful to see publications, whether 
scientific or popular, being made available to those parents and members of the 
public who are seeking more information than is contained in the educational 
pamphlet. 
6. It would be useful to see more audit, epidemiological and cost-effectiveness data 
and/or research (amongst other topics) coming out of the programme. This 
would be best undertaken by the programme itself but, given the apparently 
constrained levels of financial support and small number of key staff, this 
research might be most easily done in association with other researchers, rather 
than solely internally. Collaborative reports may also mitigate any conflict of 
interests concerns.
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7. Screening expansion is an exciting move for many and the programme expects 
that an additional five to ten children with genetic disorders will be detected 
through the programme per annum.156 The MSMS is also to be used as a 
metabolic diagnostic tool (outside newborn screening). Given the expansion 
of newborn screening, the versatility of the new technology and its potential 
for disease prevention, the purchase of the MSMS was perhaps worthy of 
better governmental support, rather than the programme’s needing to rely on a 
children’s charity for financial support. 
8. The newborn metabolic screening programme can justifiably be classed as a 
genetic service. At present, there is seemingly unofficial and ad hoc national 
co-ordination with respect to genetic services. There is currently a review of the 
2003 NHC report on co-ordination of genetic testing in New Zealand157 by the 
New Zealand District Health Boards, presumably with a view to implementation 
of at least some of the report, although there is no other information available 
on this review currently. Newborn metabolic screening should at least be 
acknowledged in future genetic co-ordination initiatives; although, equally, the 
programme legitimately belongs within the mandate of screening services.
9. Once scientifically accurate, clinically useful, cost-effective, high-throughput 
screens are available for the more controversial disorders, such as early onset, 
untreatable genetic disorders, e.g. some lysosomal or peroxisomal storage 
disorders, it would be positive to see public discussion of the pros and cons of 
inclusion of untreatable disorders. This could be a function of the Ministry 
of Health, a genetic services overview, screening services and the Bioethics 
Council, etc. If screening for untreatable disorders were to be introduced then 
there must be improved education (of and by providers) so parents are aware 
of the implications of screening for this type of disorder. Separate consent, 
although consuming more time and resources, might also be desirable in the 
implementation period, at least.
10. Any future expansion of DNA screening will require sound scientific and 
clinical justification and an extensive education campaign, including perhaps 
public consultation. Whilst the majority of the population appears to be 
comfortable with at least some aspects of genetic testing,158 failure to inform 
and discuss may be seen in a suspicious light by a small yet vocal section of the 
population, resulting in distrust in the programme and, potentially, a lowered 
participation rate in newborn screening. 
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11. Eventually, it seems likely that DNA screening for individual disorders will be 
introduced as adjunct tests to the metabolic screening programme. With the 
speed at which science is developing and innovating in genetics, it is impossible 
to say, with any certainty, what the longer-term future holds for newborn 
screening or even whether the screening time point might move to (non-
invasive?) antenatal screening. Whole genome sequencing remains likely in the 
longer term, although how and when this information might be used, after the 
initial sequencing process, remains to be seen.
12. Expansion of newborn screening into DNA screening will require more 
characterisation of minority populations in New Zealand. It is likely that there 
will be differing allele frequencies for various disorders in these populations, 
compared with populations of Northern European descent (as for cystic fibrosis 
in the United States). It is also possible that a small number of genetic disorders, 
rarely found in Northern European populations, are more commonly found in 
minority populations. If any were identified, there would be merit in evaluating 
them for screening.
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